STAT+: FDA to reconsider treatment for rare cancer after its surprise rejection

The FDA has agreed to reconsider a treatment for a rare blood cancer called Ebvallo after initially rejecting it in January. The drug's manufacturers, Pierre Fabre Pharmaceuticals and Atara Biotherapeutics, had a meeting with FDA officials in late April. The agency will now review the already completed clinical trial.